In 2020, the European Commission announced its new "Pharmaceutical Strategy for Europe" for the coming years (1). One aspect of this strategy involves a major revision of the European Union's (EU) general pharmaceutical legislation, and its legislation on rare diseases and paediatric drugs (2).
展开▼
